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Abstract
Background: In adults with febrile urinary tract infection (fUTI), data on optimal treatment duration in patients
other than non-pregnant women without comorbidities are lacking.
Methods: A randomized placebo-controlled, double-blind, non-inferiority trial among 35 primary care centers and 7
emergency departments of regional hospitals in the Netherlands. Women and men aged ≥ 18 years with a
diagnosis of fUTI were randomly assigned to receive antibiotic treatment for 7 or 14 days (the second week being
ciprofloxacin 500 mg or placebo orally twice daily). Patients indicated to receive antimicrobial treatment for at least
14 days were excluded from randomization.
The primary endpoint was the clinical cure rate through the 10- to 18-day post-treatment visit with preset
subgroup analysis including sex. Secondary endpoints were bacteriologic cure rate at 10–18 days post-treatment
and clinical cure at 70–84 days post-treatment.
Results: Of 357 patients included, 200 were eligible for randomization; 97 patients were randomly assigned to
7 days and 103 patients to 14 days of treatment. Overall, short-term clinical cure occurred in 85 (90%) patients
treated for 7 days and in 94 (95%) of those treated for 14 days (difference –4.5%; 90% CI, –10.7 to 1.7; Pnon-inferiority = 0.
072, non-inferiority not confirmed). In women, clinical cure was 94% and 93% in those treated for 7 and 14 days,
respectively (difference 0.9; 90% CI, –6.9 to 8.7, Pnon-inferiority = 0.011, non-inferiority confirmed) and, in men, this was
86% versus 98% (difference –11.2; 90% CI –20.6 to –1.8, Psuperiority = 0.025, inferiority confirmed).
The bacteriologic cure rate was 93% versus 97% (difference –4.3%; 90% CI, –9.7 to 1.2, Pnon-inferiority = 0.041) and the
long-term clinical cure rate was 92% versus 91% (difference 1.6%; 90% CI, –5.3 to 8.4; Pnon-inferiority = 0.005) for 7 days
versus 14 days of treatment, respectively. In the subgroups of men and women, long-term clinical cure rates met the
criteria for non-inferiority, indicating there was no difference in the need for antibiotic retreatment for UTI during 70–84
days follow-up post-treatment.
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Conclusions: Women with fUTI can be treated successfully with antibiotics for 7 days. In men, 7 days of antibiotic
treatment for fUTI is inferior to 14 days during short-term follow-up but it is non-inferior when looking at longer
follow-up.
Trial registration: The study was registered at ClinicalTrials.gov [NCT00809913; December 16, 2008] and trialregister.nl
[NTR1583; December 19, 2008].
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Background
In the last decade, treatment of urinary tract infections
(UTIs) has become more complicated by the rising anti-
microbial resistance of Enterobacteriaceae, the most
common uropathogens [1]. With a scarcity of new anti-
microbial classes in the development pipe-line, it is
essential to develop strategies to maintain effectiveness
of the available antimicrobials [2]. Therefore, among
strategies to control resistance, the determination of an
optimal duration of treatment is essential in addition to
optimization of diagnostics to target treatment and anti-
biotic stewardship concerning antibiotic choice and
dose. Shortening of antimicrobial therapy will lead to
less selection pressure on the gut microbiome with ben-
efits to both the individual patient as well as the eco-
logical environment, including reduction of antibiotic
resistance development [3]. Therefore, the focus upon
treatment duration of common infections should be that
shorter is better [4]. With respect to febrile UTI (fUTI)
or acute pyelonephritis, trials upon treatment duration
have usually focused on previously healthy young
women and have addressed optimal treatment duration
by comparing the same drug for different durations of
therapy, or compared various treatment durations of dif-
ferent antimicrobial agents [5]. As such, recommenda-
tions upon optimal treatment duration of UTIs in men,
the elderly, hospitalized patients, and patients with
comorbidities or bacteremia, remain unclear [5–7].
Recently, a randomized placebo-controlled trial
showed that community-acquired acute uncomplicated
pyelonephritis in women of all ages can be safely and
efficaciously treated with oral ciprofloxacin for 7 days
[8]. Clearly, such findings need to be extended to men
and patients with significant comorbidities. In the
present investigator-initiated randomized trial of treat-
ment duration, we use fUTI as the clinical syndrome of
interest because this is a broadly recognized specific
clinical presentation of patients. Consecutive patients
with fUTI were included, including men and women
with comorbidities, and treated with antibiotics for 7 or
14 days. The aims of the study were to compare clinical
and bacteriological cure at both the short and long term.
Methods
Study design and patients
We conducted a randomized, placebo-controlled, double-
blind, multicenter, non-inferiority trial; the protocol has
been published previously [9].
Consecutive women and men aged 18 years or older with
a presumptive diagnosis of community-acquired fUTI
established by a primary care physician or on presentation
at the hospital’s emergency department were screened for
enrollment. Eligible patients had all of the following criteria:
fever of ≥ 38.2 °C and/or a history of feeling feverish with
shivering or rigors in the past 24 hours, one or more symp-
toms suggestive of UTI (i.e., dysuria, frequency, urgency,
perineal or suprapubic pain, costovertebral tenderness, or
flank pain), and positive urine nitrate test and/or pyuria
(positive leucocyte esterase test or more than five leuco-
cytes per high-power field in a centrifuged sediment).
Patients enrolled were competent to provide written in-
formed consent. Exclusion criteria for study entry were
known allergy to fluoroquinolones, pregnancy or lactation,
polycystic kidney disease, permanent renal replacement
therapy, kidney transplantation, residence outside The
Netherlands, and inability to speak or read Dutch.
Contra-indications for randomization were isolation of
ciprofloxacin-resistant causal uropathogen, presence of
renal abscess, metastatic infectious foci, or underlying
chronic bacterial prostatitis as defined by recurrent UTI
with the same uropathogen. Patients enrolled with fUTI
but not randomized to trial medication, remained in the
observational part of the study to assess outcome.
The study protocol was approved by the Medical
Ethics Committee of the Leiden University Medical
Center (protocol P08.65). In addition, the independent
scientific boards of all participating hospitals assigned
for local participation. The trial was registered at
ClinicalTrials.gov (NCT00809913; December 16, 2008)
and trialregister.nl (NTR1583; December 19, 2008).
Randomization, antimicrobial treatment, and
microbiological methods
Patients were randomized in a 1:1 ratio, stratified per
center and sex, to receive either a 7-day or a 14-day
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regimen of antimicrobial treatment. A computer-
generated randomization list, including the numbers 1
to 500, with 125 permuted blocks of four was made. The
list and corresponding treatment (placebo or ciprofloxa-
cin) was saved in an independent database with
restricted access by an independent pharmacist.
Randomization, and thus treatment allocation, was done
once the results of the urine culture became available at
the third or fourth day after inclusion. The first week of
treatment was open label. In the second week, treatment
was continued double-blinded, with either ciprofloxacin
500 mg or placebo orally twice daily (identical capsules
for placebo and ciprofloxacin were used), according to
randomization code. In inpatients, the treating physician
could administer discretionary empirical intravenous an-
tibiotics at the start of treatment according to local
guidelines (in all participating centers: a β-lactam anti-
biotic ± aminoglycoside). These patients were switched
as soon as deemed possible to open label oral ciprofloxa-
cin (non-blinded) up to the seventh day after inclusion
(equal to day of presentation with febrile UTI and start
of antibiotic treatment). The decision whether to treat as
outpatient or inpatient was made by the attending phys-
ician based on clinical judgment. In case the urine
culture was negative or contaminated, patients were only
randomized if the attending physician indicated the
patient should be further treated for fUTI and no alter-
native diagnosis was made. Cultures were analyzed
according to standard microbiological methods at local
certified laboratories. For urine cultures, 10 μL of uncen-
trifuged urine was inoculated onto culture media. Plates
were investigated for growth after 18–24 h of aerobic in-
cubation at 37 °C. The amount of growth was assessed
and scored from < 100 CFU/mL (no growth) to >
105 CFU/mL.
A positive urine culture was defined as ≥ 104 CFU/mL
of urine in women, or ≥ 103 CFU/mL of urine in men,
or ≥ 102 CFU/mL of urine collected during antibiotic
treatment of UTI [9]. Further details on randomization,
trial medication, microbiological methods, and study
procedures have been previously published [9].
Main outcome measures
The primary endpoint was the clinical cure rate through
the 10- to 18-day post-treatment visit (short-term clin-
ical cure). Clinical cure was defined as being alive with
absence of fever and resolution of UTI symptoms (either
absence of symptoms or at least 2 points improvement
on a 0–5 point severity score scale), without additional
antimicrobial therapy (for relapse of UTI). Secondary
outcome measures were bacteriological cure through the
10- to 18-day post-treatment visit, clinical cure rate
through the 70- to 84-day post-treatment visit (cumula-
tive clinical cure), all-cause mortality, adverse event rate
determined at 10–18 days and 70–84 days post-
treatment, and rate of UTI relapses. In addition,
outcome measures were analyzed as stratified by specific
predefined subgroups (men, patients with complicated
UTI, older age, patients with bacteremic UTI). Bacterio-
logic cure was defined as eradication of the study entry
uropathogen with no recurrence of bacteriuria (patho-
gen growth < 104 CFU/mL in women or < 103 CFU/mL
in men of a midstream urine culture combined with
disappearance of leucocyturia) [10].
Statistical analysis
The primary endpoint was analyzed on the intention-to-
treat (ITT) population, including all randomized patients
who received at least one dose of the study drug (on the
eighth day of UTI treatment), and on the per-protocol
(PP) population, including all randomized patients who
had been given the study drug for a minimum of
24 hours (in case of treatment failure) or who had taken
at least 80% of the study drug (in case of clinical cure).
The study sample size was calculated on the basis of a
clinical cure rate of 10 percentage points lower at short-
term follow-up in the 7-day treatment arm with the
assumption of a 90% clinical cure rate in patients treated
for 14 days [11, 12]. We adopted 10% as the margin of
non-inferiority as suggested previously [13]. As we were
only interested in non-inferiority and not in equivalence,
the sample size calculation was based on a one-tailed
alpha of 0.05. Assuming a non-inferiority margin of 0.10,
1-tailed alpha of 0.05, and a power of 0.90, the required
sample size per group was 200. This implies that the
90% confidence interval of a two-tailed χ2 test should
not cross the predefined risk difference of 10% lower
clinical cure rate, or equivalently, the one-sided P value
is less than the 0.05 significance level [14]. Interim ana-
lyses were done after randomization of 100 and 200
patients. After the second interim analysis, there was no
reason to stop the trial for safety reasons. However, the
principal investigators, who obviously were still blinded
with respect to treatment allocation, noted that the over-
all cure rate was 92%. This is comparable with the
results of a recently published similar trial in women
comparing 73 to 83 patients treated over 7 or 14 days,
respectively [8]. As we had indeed included a larger sam-
ple size of 200 patients, we estimated that our study
would likely have already met the criteria for non-
inferiority while still having a power of 0.80 with a type
1 error of 0.05. As we were confronted with an almost
empty budget and a dropping inclusion rate after almost
5 years of participation, we considered continuation of
the trial was no longer realistic and thus we decided to
stop the trial at this point.
Descriptive statistics were used to describe the base-
line characteristics in each arm with χ2 tests for binomial
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and categorical data and Mann–Whitney tests for con-
tinuous data. All analyses were performed using SPSS
20.0 (SPSS Inc., Chicago, IL, USA). Confidence intervals
around the risk difference were calculated using Episheet
(www.krothman.org) and P values for non-inferiority
were calculated accordingly. Interaction between prede-
fined covariables and treatment was tested by calculating
a P value for difference in risk differences between
subgroups.
Results
Between November 2008 and May 2013, 357 patients
with a diagnosis of fUTI were enrolled into the study. Of
these, 200 were randomly assigned to receive antimicro-
bial treatment for 7 (n = 97) or 14 (n = 103) days.
Reasons for exclusion from randomization, ITT, and PP
analyses are listed in Fig. 1.
Of the 157 non-randomized patients, 119 (76%) were
evaluable for short-term efficacy and 116 (74%) for
cumulative efficacy.
Baseline characteristics of the study population are
summarized in Table 1.
Randomized, evaluable subjects in the two treatment
arms were well matched with respect to demographic
characteristics and presentation on study entry. The 157
patients who were not randomized, generally had more
comorbidities and were more frequently referred to the
emergency department. Additional details are listed in
Additional file 1. Baseline urine cultures were performed
in 341 patients (96%) (Table 2).
In 99 (28%) patients, urine culture showed either no
significant bacteriuria or a mixed flora; in over half of
these cases (58%), patients were pre-treated with antibi-
otics (group randomized to 7 days: 13 (59%); group ran-
domized to 14 days: 20 (63%)); a similar percentage
pertained to those not randomized (n = 23, 51%).
Blood cultures were obtained in 339 patients, of which
80 (24%) had bacteremia with growth of E. coli in the
majority of the cases (n = 67, 84%).
Both treatment regimens resulted in a high clinical
cure rate at short-term follow-up in the ITT population
Fig. 1 Trial profile. * concurrent medical conditions (n = 16), logistic reasons (n = 5), abroad during treatment with study medication (n = 3)
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(90% vs. 95% in patients treated for 7 or 14 days,
respectively) (Table 3). The difference in short-term clin-
ical cure rate between both treatment arms was 4.5%
(90% CI, –10.7 to 1.7, Pnon-inferiority = 0.072). Accordingly,
the criteria for non-inferiority were not met as the 90%
CI exceeded the predefined non-inferiority margin of
10%. The median time to defervescence did not differ
between the two groups: 2 (IQR, 1–2) days in 7-day
antimicrobial treatment, 2 (IQR, 1–3) days in 14-day
antimicrobial treatment. Short-term clinical cure was
85% in non-randomized patients, whereas median time
to defervescence amounted to 2 (IQR, 1–3) days. Among
all analysis performed, there were no significant differ-
ences between ITT and PP analysis. Therefore, within
the following, only outcomes of ITT analysis are
presented.
Table 1 Baseline characteristics of 357 patients with febrile urinary tract infection
Randomized (n = 200) Not randomized
(n = 157)
P valuec
Antibiotic treatment for 7 days
(n = 97)
Antibiotic treatment for 14 days
(n = 103)
Age (years) 60 (48–72) 61 (40–73) 63 (49–75) 0.277
Male sex 44 (45%) 42 (41%) 58 (37%) 0.247
Body mass index (kg/m2, mean, SD) 26.3 (5.2) 25.8 (4.5) 26.1 (4.9) 0.969
Urologic history
Indwelling urinary catheter 3 (3%) 2 (2%) 12 (8%) 0.024
Urinary tract disordera 28 (29%) 28 (27%) 52 (33%) 0.296
Recurrent UTIb 19 (20%) 19/100 (19%) 47/147 (32%) 0.007
Comorbidity
Diabetes mellitus 12 (12%) 17 (17%) 25 (16%) 0.709
Malignancy 3 (3%) 5 (5%) 17 (11%) 0.012
Heart failure 12 (12%) 6 (6%) 19 (12%) 0.340
Cerebrovascular disease 5 (5%) 5 (5%) 13 (8%) 0.210
Chronic renal insufficiency 3 (3%) 2 (2%) 10 (6%) 0.070
COPD 10 (10%) 11 (11%) 23 (15%) 0.236
Immunocompromised 3 (3%) 8 (8%) 14 (9%) 0.209
Signs and symptoms at presentation
Presentation at emergency department 59 (61%) 68 (66%) 145 (92%) <0.001
Antibiotic pretreatment 23 (24%) 29 (28%) 56 (36%) 0.048
Fever duration, hours 30 (15–48) 36 (20–60) 48 (19–96) 0.081
Dysuria 82/95 (86%) 78/102 (77%) 102/145 (70%) 0.019
Flank pain 57/96 (59%) 67/102 (66%) 91/144 (63%) 0.914
Suprapubic pain 51/96 (53%) 48/100 (48%) 72/145 (50%) 0.876
Perineal pain 4/96 (4%) 7/98 (7%) 8/140 (6%) 0.986
Shaking chills within previous 24 hours 63/97 (65%) 60/101 (59%) 102/149 (70%) 0.256
Temperature > 38 °C 66 (68%) 76 (74%) 121 (77%) 0.226
Systolic blood pressure (mm Hg, mean, SD) 132 (19) 132 (22) 129 (20) 0.324
Pulse rate (beats/minute) 93 (17) 94 (19) 97 (19) 0.360
Outpatient treatment 45 (46%) 45 (44%) 23 (15%) <0.001
Positive urine culture 69 (71%) 68 (66%) 107 (68%) 0.944
Positive blood culture 20/88 (23%) 15/98 (15%) 45/153 (29%) 0.012
Positive urine and/or blood culture 75 (77%) 70 (68%) 118 (75%) 0.571
Initial intravenous dose(s) of antibiotics 48 (50%) 55 (53%) 133 (85%) < 0.001
Data presented as number (%) or median (IQR)
COPD chronic obstructive pulmonary disease, UTI urinary tract infection
aAny functional or anatomical abnormality of urinary tract except urinary catheter
bThree or more UTIs in past 12 months or two or more UTIs in past 6 months
cRandomized (both 7 and 14 days ciprofloxacin) vs. not-randomized patients
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Short-term clinical cure rates were analyzed in preset
subgroups of patients. In women, short-term clinical
cures for the 7- and 14-day arms were 47 of 50 (94%)
versus 54 of 58 (93%), respectively. The difference in
cure rate was 0.9% (90% CI, –6.9 to 8.7, Pnon-inferiority =
0.011, non-inferiority confirmed). In men, clinical cure
rates differed significantly between those treated for 7 or
14 days (38 of 44; 86% vs. 40 of 41; 98%) (Fig. 2). The
difference in cure rate was –11.2 (90% CI, –20.6 to –1.8,
Pnon-inferiority = 0.417, Psuperiority 2-sided = 0.050, superiority
of 14-days treatment confirmed). The large difference in
risk differences for age was predominantly determined
by men. Therefore, and for explorative reasons, an add-
itional subgroup analysis was also performed within the
group of men and women. The results are presented in
Additional file 1: Figure S1 and Figure S2, respectively.
For stepdown treatment, bacteremia, and complicated
UTI, the risk differences were similar between the
subgroups and in all subgroups, non-inferiority was not
shown.
For cumulative clinical cure rate (70 to 84 days post-
treatment), 94 patients were evaluable in each treatment
arm. Clinical cure rates were high: 93% vs. 91% in
patients treated for 7 or 14 days; difference 1.1% (90%
Table 2 Urine culture results at entrya
Randomized Not randomized
Antibiotic treatment for 7 days Antibiotic treatment for 14 days
Escherichia coli 65 (68%) 65 (59%) 85 (51%)
Klebsiella spp. 2 (2%) 4 (4%) 13 (8%)
Proteus spp. 1 (1%) 6 (5%) 6 (4%)
Pseudomonas aeruginosa – – 2 (1%)
Enterococcus spp. 1 (1%) – 8 (5%)
Staphylococcus spp. – – 1 (1%)
Otherb 3 (3%) 3 (3%) 8 (5%)
None or contaminated culture 22 (23%) 32 (29%) 45 (27%)
Data presented as number (%). Urine culture performed in antibiotic treatment for 7 days: 91 (94%), antibiotic treatment 14 days: 100 (97%), non-randomized:
150 (96%)
aSome patients had multiple isolates; antibiotic treatment 7 days: n = 6, antibiotic treatment 14 days: n = 10, not randomized n = 17
bAntibiotic treatment 7 days: Proteus mirabilis (n = 1), Citrobacter sedlakii (n = 1), Citrobacter koseri (n = 1), Candida spp. (n = 2); Antibiotic treatment 14 days:
Morganella morganii (n = 1), β-hemolytic streptococci (n = 2); Not randomized: Serratia marcescens (n = 1), β-hemolytic streptococci group B (n = 1), Enterobacter
cloacae (n = 1), Streptococcus bovis (n = 1), Citrobacter koseri (n = 1), Morganella morganii (n = 1), Proteus mirabilis (n = 1), β-hemolytic streptococci (n = 1)
Table 3 Clinical and bacteriologic outcomes in the intention-to-treat and per-protocol population







Intention-to-treat population (n = 94) (n = 99)
Short-term efficacya (n = 94) (n = 99) (n = 119)
Clinical cureb 85 (90.4%) 94 (94.9%) –4.5% (–10.7 to 1.7) 0.072 101 (84.9%)
Bacteriologic curec 86/93 (92.5%) 89/92 (96.7%) –4.3% (–9.7 to 1.2) 0.041 94/109 (86.2%)
Cumulative efficacyd (n = 94) (n = 94) (n = 116)
Clinical cureb 87 (92.6%) 86 (91.5%) 1.1% (–5.5 to 7.6) 0.005 88 (75.9%)
Per-protocol population (n = 92) (n = 92)
Short-term efficacya (n = 92) (n = 92) NA
Clinical cureb 83 (90.2%) 87 (94.6%) –4.3% (–10.8 to 2.1) 0.073
Bacteriologic curec 84/91 (92.3%) 83/86 (96.5%) –4.2% (–9.9 to 1.4) 0.045
Cumulative efficacyd (n = 92) (n = 87)
Clinical cureb 85 (92.4%) 79 (90.8%) 1.6% (–5.3 to 8.4) 0.005
Data presented as number (%), unless otherwise indicated. NA: not applicable
aShort-term efficacy: endpoints assessed at 10- to 18-days post-treatment visit
bClinical cure: being alive with absence of fever and resolution of UTI symptoms through post-treatment visit with no additional antimicrobial therapy for a relapse
of UTI prescribed
cBacteriologic cure: elimination of study entry uropathogen or pathogen growth < 104 CFU/mL (women) or <103 CFU/mL (men) combined with disappearance
of leucocyturia
dCumulative efficacy: endpoint assessed at 70- to 84-days post-treatment visit
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CI, –5.5 to 7.6, Pnon-inferiority = 0.005, non-inferiority
confirmed) (Table 3). Criteria for non-inferiority for
cumulative clinical cure rate were also met for the sub-
groups men and women (Additional file 1: Table S1).
Both treatment regimens post-randomization, were
well tolerated with no differences in side effects
(Additional file 1).
Post-treatment urine cultures (at days 28–32) were
obtained in 93 of 94 (99%) patients assigned to 7 days, in
92 of 99 (93%) patients assigned to 14 days of antimicro-
bial treatment, and in 109 of 119 (92%) non-randomized
patients, with the short-term follow-up visit. Bacteriologic
cure was 91% in the 7-day treatment arm, 97% in patients
treated for 14 days, and 86% in non-randomized patients
(Table 3). More details on clinical and microbiological
outcomes are listed in Additional file 1.
Discussion
Our findings show that community-acquired fUTI can
be safely and efficaciously treated with antimicrobial
treatment for 7 days in women as it is non-inferior to
14 days of therapy. However, in men with fUTI, the
7-day treatment was significantly inferior to 14 days of
treatment.
The main strength of this trial is its pragmatic nature
reflecting daily clinical practice with the inclusion of con-
secutive patients with fUTI, both men and women, irre-
spective of age and underlying medical conditions, with
the notable exception of those with severe kidney disease,
antibiotic allergy, and pregnancy. Several hospitals were
involved, including a referral university hospital, and
general practitioners, who enrolled about one fourth of
our patients. Therefore, patients recruited into the study
are considered representative of individuals with acute
community-acquired fUTI, encompassing acute pyelo-
nephritis, prostatitis, and the urosepsis syndrome. Over
55% of patients were initially hospitalized because of fUTI,
likely because of presumed urosepsis syndrome, and a
relative high number of patients had bacteremia. Of note,
the findings hold for both the ITT and the PP analyses,
underlying the high compliance by patients randomized
with respect to the treatment protocol and precluding that
poor study procedures may have concealed differences in
patient management. Finally, the clinical cure rate at
90 days after initial presentation with fUTI was evaluable
in 188 (94%) patients and, though characterized as a
secondary outcome measure, for the whole group as well
as the subgroups of men and women, they all met the
criteria for non-inferiority.
There are, however, also some limitations. First of all,
the diagnosis of fUTI was not confirmed by cultures for
all patients. Nevertheless, it should be noted that the
attending physicians still made a clinical diagnosis of
fUTI is such cases, and no alternative diagnosis for fever
or urinary tract symptoms was made. Secondly, our
study lacks statistical power to draw confident conclu-
sions on the various subgroups because of the limited
number of patients enrolled. However, it should be
noted that all subgroups analyzed were predefined in the
study protocol. Finally, it should be noted that several
Fig. 2 Difference in clinical cure rates (10- to 18-days post-treatment) of febrile UTI treated for 7 days versus 14 days in specific subgroups.
Stepdown treatment implies initial empiric intravenous antibiotic treatment. UTI urinary tract infection; CI confidence interval. P values represent
test for interaction. Data presented from intention to treat analysis
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patient categories (e.g., ciprofloxacin-resistant uropatho-
gen, renal transplant, pregnancy, indication for
antimicrobial treatment for at least 14 days) were
excluded from randomization. Thus, our findings might
not be generalizable to all patients with fUTI.
Our findings extend recent findings of a highly similar
controlled randomized Swedish study performed in
women with acute pyelonephritis, showing non-inferiority
of 7- to 14-days of antimicrobial treatment [8]. Compared
to our study, their patient group was younger, had less co-
morbidities, and fewer had complicated UTIs.
In men, our results indicate an increase in the rate of
clinical and bacteriological treatment failure after the 7-
day treatment as compared to 14 days. Likely, though
chronic bacterial prostatitis was an exclusion criterion,
this is due to prostatic involvement of the infection as this
is known to be a cause of recurrent UTI, even after appro-
priate antimicrobial treatment [15]. There is a lack of
studies on optimal treatment duration of fUTI in men [5].
One study directly compared different treatment duration
in an open, prospective, and randomized trial in 72 men
with community-acquired fUTI, showing similar bacterio-
logical cure rates with ciprofloxacin 500 mg orally twice
daily for either 2 or 4 weeks [16]. Similarly, a randomized,
double-blind trial in Sweden lent support for the efficacy
of 14-day treatment with fluoroquinolones in men [17].
Taken together, the studies confirm that, at present, a 14-
day treatment regimen of fluoroquinolones is the mini-
mum period necessary for optimal therapy of fUTI in
men. Recently, however, a retrospective analysis of a large
database of male veterans indicated that more than 7 days
of antibiotic treatment (the vast majority being treated
with ciprofloxacin) was not associated with a reduction of
UTI recurrence [18]. In addition, this study showed that
treatment with β-lactams was associated with a higher risk
of recurrence as compared to fluoroquinolone treatment.
Furthermore, they showed that UTI recurrence was inde-
pendently associated with comorbidities and age. As in
our study about half of the patients were initially treated
with a β-lactam intravenously, implying less penetration
into the prostrate [19], this may have influenced our results
and may possibly explain the larger difference in cure rates
within the subgroup of men with stepdown treatment.
Interestingly, in line with this, we found no significant dif-
ference in men who were solely treated with ciprofloxacin,
whereas in men aged less than 50 years, there was a similar
cure rate with antibiotic treatment for 7 or 14 days.
Nevertheless, it should be noted that there were similar
clinical cure rates between 7 and 14 days of treatment
during longer follow-up (70–84 days post-treatment) and
this holds both for women and men. In others words, the
need for additional antibiotic UTI treatment during longer
follow-up is similar irrespective of whether the initial
treatment of fUTI was 7 or 14 days. Given the principles
of antimicrobial stewardship, this is an interesting finding
because, even in men with fUTI, this might be an
argument to treat them for 7 days. Indeed, our study indi-
cates that a further study upon treatment duration of men
with fUTI should be performed, including outcome mea-
sures being set at 3 months or even longer instead of the
traditional 2–6 weeks.
Given the consistency of our findings and those of the
recent study in Sweden [8], we conclude that women with
fUTI, irrespective of disease severity and comorbidities,
can be treated orally with 7 days of adequately dosed
fluoroquinolones. Ciprofloxacin was chosen as treatment
because of its reliable intestinal resorption and bioavail-
ability, and excellent antimicrobial activity against a broad
spectrum of susceptible gram-negative uropathogens,
making it a drug of choice in both outpatient as well as
hospital settings. As a surplus, activity against perineum
and vagina colonizing Enterobacteriaceae may help to pre-
vent early recurrences [20]. An important concern has
been the rise of ciprofloxacin resistance in the community,
i.e., up to 15% of Enterobacteriaceae are currently resistant
in The Netherlands, that may preclude the use of fluoro-
quinolones as first-choice empiric oral treatment of fUTI.
Of great concern, in other countries, this figure has been
reported as high as 40–50% [21, 22]. In countries with
concurrent high rates of trimethoprim-sulfamethoxazole
resistance in Enterobacteriaceae, there may be no oral
antibiotic option left for general practitioners to treat fUTI
at home, raising healthcare costs. These findings under-
score the importance of controlling antimicrobial resist-
ance through antibiotic stewardship, including the
administration of antibiotics with optimal duration [4, 23].
Conclusions
Women with fUTI can be successfully treated with anti-
biotics for 7 days, including those who initially were
treated with β-lactams intravenously. In men, 7 days of
antibiotic treatment for fUTI is inferior to 14 days when
looking at short-term clinical cure. During long-term
follow-up, even in men, 7 days of antibiotic treatment is
non-inferior to 14 days.
Is should be considered that the primary outcome
measures on future trials on antibiotic treatment dur-
ation of fUTI in men, should be set at 3 months instead
of the traditional 2 weeks.
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